Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 9/20 | 0.53 |
| ▸ | MTOR | P42345 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ALPL | P05186 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7996257 | 0.95 | PIK3CA (0.55) | PIK3CAMTORMAPK1ALPLEGFR | |
| SCHEMBL8008298 | 0.93 | PIK3CA (0.55) | PIK3CAMTORMAPK1EGFRCDK2 | |
| SCHEMBL8008138 | 0.92 | PIK3CA (0.52) | PIK3CAMTORMAPK1EGFRCDK2 | |
| SCHEMBL17244446 | 0.92 | ALPL (0.44) | PIK3CAMTORALPLCDK1 | |
| SCHEMBL13597813 | 0.90 | PIK3CA (0.54) | PIK3CAMTORMAPK1EGFRCDK2 | |
| SCHEMBL1552132 | 0.90 | PIK3CA (0.55) | PIK3CAMTORMAPK1EGFRCDK2 | |
| SCHEMBL8006058 | 0.90 | PIK3CA (0.54) | PIK3CAMTORMAPK1EGFRCDK2 | |
| SCHEMBL8008169 | 0.90 | PIK3CA (0.50) | PIK3CAMTORMAPK1EGFRCDK2 | |
| SCHEMBL8005712 | 0.90 | PIK3CA (0.53) | PIK3CAMTORMAPK1EGFRCDK2 | |
| SCHEMBL8008105 | 0.90 | PIK3CA (0.53) | PIK3CAMTORMAPK1EGFRCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250160-B1 | THIOPHENES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS | MILLENNIUM PHARM INC (US) | 2015-11-11 | — | — | EP | disclosed |
| US-9029411-B2 | Thiophenes and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20090325925-A1 | Thiophenes and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2009094224-A1 | THIOPHENES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325925-A1 | Thiophenes and uses thereof | PIK3CA, JAK2, MTOR | PIK3CA 1/4885MTOR 3/4885MAPK1 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.